Functional decline over time in patients with IPF treated with pirfenidone: the PROOF registry
W. Wuyts (Leuven, Belgium), C. Dahlqvist (Yvoir, Belgium), H. Slabbynck (Antwerp, Belgium), M. Schlesser (Luxembourg City, Luxembourg), N. Gusbin (Liège, Belgium), C. Compere (Brussels, Belgium), S. Maddens (Kortrijk, Belgium), K. Kirchgaessler (Basel, Switzerland), K. Bartley (South San Francisco, CA, United States of America), B. Bondue (Brussels, Belgium)
Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
W. Wuyts (Leuven, Belgium), C. Dahlqvist (Yvoir, Belgium), H. Slabbynck (Antwerp, Belgium), M. Schlesser (Luxembourg City, Luxembourg), N. Gusbin (Liège, Belgium), C. Compere (Brussels, Belgium), S. Maddens (Kortrijk, Belgium), K. Kirchgaessler (Basel, Switzerland), K. Bartley (South San Francisco, CA, United States of America), B. Bondue (Brussels, Belgium). Functional decline over time in patients with IPF treated with pirfenidone: the PROOF registry. 2201
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: